about
Mechanisms of dengue virus-induced bone marrow suppressionDengue viremia titer, antibody response pattern, and virus serotype correlate with disease severityImmunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy AdultsSafety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.Antiserum generated by DNA vaccine binds to hepatitis E virus (HEV) as determined by PCR and immune electron microscopy (IEM): application for HEV detection by affinity-capture RT-PCR.Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete exampleEvaluation of dengue virus strains for human challenge studies.Antibody-enhanced binding of dengue-2 virus to human platelets.Dengue infection complicated by severe hemorrhage and vertical transmission in a parturient woman.Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesEvidence that rodents are a reservoir of hepatitis E virus for humans in Nepal.A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialA Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenA randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of ageA model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU).Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies.AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine.HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais.
P50
Q24570138-4B73F735-4394-4931-94F5-5B1EC3D286DEQ27860703-8A933D46-2AF8-4A2C-9C4B-CF189D19BD58Q30151798-65E5560D-7C99-4F36-8434-60D97F97BDA9Q30227196-7DE7F67B-96A4-4D33-8086-393C03601FD6Q30360483-534995BE-0185-4B41-8B5B-50F76025ECE1Q30367603-364A12FD-2F5D-414C-8776-10197103E5FBQ30369467-76FC890F-4A10-4354-B53B-D3243F1FF2B5Q30372167-180E17BB-E201-4B68-BC09-BAD6DBCA0B02Q30398484-F3199A36-0FD5-4644-9D2C-2EA1EFAFAB74Q30400007-426C79EC-595A-43FD-B22D-1E6CECD8BE4DQ30787318-EBA445CC-ACF9-4226-85CD-F03F8C5EC9F9Q30857100-4BB12397-156F-4049-BB7A-CB8D691789B8Q33412959-86ACD044-6A5B-4FDB-AA27-80925F4E1A38Q33487534-F12C7FFE-C76A-4575-8E7A-BEB8D45AAD92Q33492539-E440632F-799F-4E0E-9342-494EE7D1EF3EQ34274845-776AE564-9164-4A73-ADC9-3B01C08B84A4Q34989483-9E638456-05F4-4845-946A-97319BF72A34Q35114177-B7CE75D9-5A3C-446D-8F38-EA0D45B1D21BQ35272502-01801F41-77C2-413F-8E24-272DE8530477Q36009631-AA791615-E1D2-4322-B8F9-E1A842681323Q36026204-83109DCE-B08B-47C4-9939-2A6D5CCA8093Q36377372-D1420061-F959-494C-B4AA-68FDC19F407CQ36523070-C521BE8A-2824-4FDF-AC86-6BBAD5C82A79Q37037095-92CF45D7-4715-41A4-B206-4B95A3540498Q37530395-1D0DC5BD-2DEB-4325-A59E-BA81408A2612Q38128110-8CED61F9-4E80-433B-A6D2-5129FCF8A566Q38184142-98FFB96A-D1CF-4BFC-A0FE-1B45A117DCCEQ38377686-EFB7A604-3B96-4B2B-9F77-B0ABA1538ADCQ38524522-09C22AEC-C88F-41A4-8E03-672B249B11F5Q38660898-E01F9386-B81A-4763-ADFE-5AA598F9237CQ39143927-05274F32-D44C-4FB5-8793-755E4413858EQ39447289-ED228FE3-D5E9-4F20-BF33-6E194981A0DDQ39955421-FB1C8955-F590-4DA5-B9FE-29A3509E1C0CQ40265040-6FE577A6-0231-4C17-A96A-B244F1B4585BQ40285869-73F03C68-986E-43EA-8910-72BFCEBADEF2Q40318917-0AB8B94B-F6B7-4C73-B825-264F6EC4C208Q40479018-D6BAA19E-F705-47F4-B0C8-74A246C28A8CQ40504189-EECDEF04-2F34-40E2-9B9D-B4A7B35DE551Q40507053-F17E6713-77D3-4D93-BDA9-59567E693C58Q40569492-9D1D302C-36A5-45B9-BD3D-F237D6F97354
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruce L Innis
@nl
Bruce L Innis
@sl
Bruce L. Innis
@en
Bruce L. Innis
@es
type
label
Bruce L Innis
@nl
Bruce L Innis
@sl
Bruce L. Innis
@en
Bruce L. Innis
@es
prefLabel
Bruce L Innis
@nl
Bruce L Innis
@sl
Bruce L. Innis
@en
Bruce L. Innis
@es
P106
P1153
7006230400
P21
P31
P496
0000-0002-1753-7248